10-1074
Phase 1
10-1074 is one of 55 therapeutic programs targeting HIV infection. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Videx
Bristol-Myers SquibbApproved
Ninlaro
TakedaApproved
Rifadin
SanofiApproved
Soriatane
GSKApproved
Niacor
AbbVieApproved
Jakafi
IncyteApproved
Neoral
NovartisApproved
Marinol
Jazz PharmaceuticalsApproved
Crestor
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
HIV infection1 trial
A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04340596·118 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 10-1074. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]